Physician profile

Roy Charles Brownlow

Interventional Pain Medicine · San Diego, CA

NPI 1205949914

$6,148.55

in general payments reported to CMS, 2019-2025

43 companies · $205 in 2025

The $205 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).

See the full distribution for Interventional Pain Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,721.56
Travel and Lodging$234.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Spinal Simplicity, LLC $1,842.94 2021-2023 Ha Minuteman G3-R
Abbott Laboratories $1,027.57 2019-2025 Proclaim, Prodigy, Eterna
Boston Scientific Corporation $683.82 2019-2025 Wavewriter Alpha Prime 16, Intracept
Nevro Corp. $665.75 2019-2024 Senza
Si-Bone, INC. $312.65 2024
Collegium Pharmaceutical, INC. $274.29 2019-2024 Belbuca, Xtampza
Painteq LLC $133.50 2022-2024 Painteq
Abbvie INC. $120.84 2022-2023 Qulipta, Ubrelvy
Scilex Pharmaceuticals INC. $87.90 2019-2024
Stimwave Technologies Incorporated $84.14 2019-2022
Amgen INC. $83.07 2020
Medtronic, INC. $76.19 2022
Biotronik Nro, INC. $72.79 2025 Prospera
Curonix LLC $69.00 2024-2025 Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Epimed International, INC $60.83 2019
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Avanos Medical $43.89 2022
Pacira Therapeutics, INC. $39.26 2019-2020
Electronic Waveform Lab, INC. $36.85 2022
Biohaven Pharmaceutical Holding Company LTD. $35.73 2022
Vertiflex, INC. $32.84 2019
Horizon Therapeutics Plc $32.30 2020-2022
Upsher-Smith Laboratories LLC $27.29 2019-2020
Radius Health, INC. $26.73 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $26.41 2019-2023 Relistor
Biohaven Pharmaceuticals, INC. $25.69 2021
Merz Pharmaceuticals, LLC $24.27 2022
Daiichi Sankyo INC. $21.96 2022
Bioventus LLC $20.35 2024 Supartz Fx Sodium Hyaluronate
Pfizer INC. $17.90 2023
Biodelivery Sciences International, INC. $17.86 2021
Nalu Medical, INC. $17.18 2024 Nalu Neurostimulation System
Bausch Health US, LLC $16.98 2019
Lundbeck LLC $16.55 2022
Novartis Pharmaceuticals Corporation $16.17 2020
Kowa Pharmaceuticals America, INC. $13.52 2022
Assertio Therapeutics, INC. $12.19 2019
Zyla Life Sciences, INC. $11.73 2020
Medtronic USA, INC. $11.54 2020
Fidia Pharma USA INC. $8.08 2019

4 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Roy Charles Brownlow

$6,148.55

in general payments reported 2019-2025

Years
2019-2025
Top company
Spinal Simplicity, LLC
Context
The $205 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).

https://glasscript.com/doctor/191188/roy-charles-brownlow

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.